Fully human IgG1-like bispecific monoclonal antibody that binds EGFR and MET to block ligand binding and receptor activation, suppressing downstream signaling (e.g., MAPK and PI3K/AKT) with potential Fc-mediated effector functions such as ADCC/ADCP against target-expressing tumor cells.